<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476953</url>
  </required_header>
  <id_info>
    <org_study_id>20-003936</org_study_id>
    <nct_id>NCT04476953</nct_id>
  </id_info>
  <brief_title>Covid-Fisetin: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation</brief_title>
  <official_title>Covid-Fisetin: A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Hospitalized Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in
      preventing an increase in the disease's progression and alleviate complications of
      coronavirus due to an excessive inflammatory reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured
      by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and
      hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen
      requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/
      critical proven COVID-19 (CoV) infection (WHO/NIH Baseline Severity Classification) in
      non-ICU hospitalized patients and to evaluate the safety and tolerability of Fisetin in this
      patient population.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants to experience serious adverse events and hypersensitivity reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in oxygenation status</measure>
    <time_frame>baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6</time_frame>
    <description>change in oxygenation levels as measured by S/F ratio (SPO2/FiO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 Severity Category</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants to progress to severe or critical classification measure by the WHO/ NIH Baseline Severity Classification criteria descriptions of SARS-CoV-2 infection without symptoms, Mild COVID-19 (CoV), Moderate CoV, Severe CoV and Critical CoV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment drug Fisetin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo looks exactly like the study drug, but it contains no active ingredient.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>~20 mg/kg/day oral, NG or D tube course for 2 consecutive days</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>3,3',4',7-tetrahydroxyflavone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently hospitalized in a Mayo Clinic hospital.

          -  Age ≥ 60 years admitted for CoV infection to non-ICU beds at Mayo Clinic.

          -  Willing and able to provide written informed consent, or with a LAR who provides
             informed consent, or enrolled under ICH E6(R2) 4.8.15 emergency use provisions as
             deemed necessary by the investigator (participants ≥ 60 years of age) prior to
             performing study procedures.

          -  SARS-CoV-2 infection confirmed by PCR test before randomization.

          -  Men or post-menopausal women.

        General Exclusion Criteria:

          -  Patient or LAR unable or unwilling to give informed consent.

          -  Presence of any condition that the Investigator or the subject's attending physician
             believes would put the subject at risk or would preclude the patient from successfully
             completing the trial.

          -  Mechanically ventilated (including V-V ECMO or V-A ECMO).

        Laboratory Exclusion Criteria:

          -  Total bilirubin &gt; 3 x upper limit of normal.

          -  Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) &gt; 4 x the upper
             limits of normal.

          -  Hemoglobin &lt; 7 g/dL; white blood cell count ≤ 2,000/mm^3 (≤ 2.0 x 10^9/L) or ≥
             20,000/mm^3 (≥ 20 x 10^9/L); platelet count ≤ 60,000/μL (≤ 60 x 10^9/L); absolute
             neutrophil count ≤ 1 x 10^9/L; lymphocyte count &lt; 0.5 x 10^9/L at screening.

          -  Unstable major cardiovascular, renal, endocrine, immunological, or hepatic disorder.

        eGFR &lt; 25 ml/ min/ 1.73 m^2.

          -  Plasma glucose &gt; 300.

          -  Cystatin C &gt; 3 x upper limit of normal.

        Clinical History Exclusion Criteria:

          -  Human immunodeficiency virus infection.

          -  Known active hepatitis B or C infection.

          -  Invasive fungal infection.

          -  Uncontrolled pleural/pericardial effusions or ascites.

          -  New/active invasive cancer except non-melanoma skin cancers.

        Medication Exclusion Criteria:

          -  Known hypersensitivity or allergy to Fisetin.

          -  Subjects taking medications that are sensitive to substrates or substrates with a
             narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or
             inducers of CYP3A4 (e.g., cyclosporine, tacrolimus, or sirolimus). If antifungals are
             absolutely necessary from an infectious disease perspective, then they will be allowed
             only if the levels are therapeutic.

          -  Strong inhibitors of CYP3A4.

          -  Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold
             therapy 2 days prior to and during the Fisetin dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

